PremiumCompany AnnouncementsCreative Medical Technology Approves Executive Bonuses Creative Medical announces agreements for exercise of warrants Creative Medical Technology comments on presidential initiative for IVF access PremiumThe FlyCreative Medical advances FDA cleared ADAPT trial with independent review Creative Medical Technology files to sell 837,104 shares of common for holders Creative Medical to sell 418,552 shares at $4.42 in registered direct offering PremiumThe FlyCreative Medical gets FDA authorization for CELZ-201 expanded access therapy Creative Medical Technology gets orphan drug designation from FDA for CELZ-101 Creative Medical Technology’s CELZ-101 granted FDA orphan designation